Details of the Drug
General Information of Drug (ID: DMFGND4)
Drug Name |
Aminocaproic acid
|
|||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
6-Aminohexanoic acid; 6-aminohexanoic acid; 6-Aminocaproic acid; aminocaproic acid; 60-32-2; amicar; Epsikapron; Caprocid; Capramol; Epsamon; EACA; Caprolisin; Acepramin; Hemocaprol; Epsicapron; Respramin; Amikar; EPSILON-AMINOCAPROIC ACID; Hexanoic acid, 6-amino-; Epsilcapramin; Aminokapron; Caplamin; Acepramine; Capracid; Hemopar; Ipsilon; Afibrin; Atsemin; Hepin; Epsilon S; Aminocaproic; Capralense; epsilon-Leucine; EACS; epsilon-Norleucine; epsilcapramine; 6-Amino-n-hexanoic acid; omega-Aminocaproic acid; epsilon-Aminohexanoic acid; 6-amino-hexanoic acid; ACS; Amicar; Aminocaproate; Capranol; Caproamin; Epsicaprom; Epsilcapramine; Hemopar;Hepin; Acide aminocaproique; Acide aminocaproique [French]; Acide aminocaproque; Acido aminocaproico; Acidum aminocaproicum; Acidum aminocaproicum [Latin]; Aminocaproic Acid In Plastic Container; Aminocaproic Acids; Aminohexanoic acid; Eaca kabi; Epsilon Aminocaproic Acid; A 7824; CL 10304; CY 116; CY116; JD 177; Acide aminocaproique [INN-French]; Acido aminocaproico [DCIT,Spanish]; Acido aminocaproico [INN-Spanish]; Acidum aminocaproicum [INN-Latin]; Amicar (TN); Aminocaproic acid (USP); CL-10304; CY-116; Epsilon-Ahx; Epsilon-Aminocaproic acid; Epsilon-Aminocapronsaeure; Epsilon-Aminohexanoic acid; Epsilon-Leucine; Epsilon-Norleucine; Epsilon-aminocaproate; Epsilon-aminocapronzuur; Fullevir (TN); Kyselina omega-aminokapronova; Kyselina omega-aminokapronova [Czech]; Omega-Aminocaproic acid; Omega-Aminohexanoic acid; S04-0132; Acid, 6-Aminocaproic; Acid, 6-Aminohexanoic; Acid, epsilon-Aminocaproic; Aminocaproic acid (USP/INN); Aminocaproic acid [USAN:BAN:INN]; Aminocaproic acid [USAN:INN:BAN]; Epsilon-Aminocaproic acid (JAN); HEXANOIC ACID,6-AMINO; Epsilon-Amino-n-caproic acid; Epsilon-Amino-n-hexanoic acid; Amicar, A-amino caproic acid, A-Ahx, 6-aminohexanoic acid, Aminocaproic acid; 6 Aminocaproic Acid; 6 Aminohexanoic Acid; 6-amino-n-caproate; 6-amino-n-caproic acid; 6-aminohexanoate; 6-Amino Hexanoic Acid
|
|||||||||||||||||||||||
Indication |
|
|||||||||||||||||||||||
Therapeutic Class |
Antifibrinolytic Agents
|
|||||||||||||||||||||||
Drug Type |
Small molecular drug
|
|||||||||||||||||||||||
Structure | ||||||||||||||||||||||||
3D MOL | 2D MOL | |||||||||||||||||||||||
#Ro5 Violations (Lipinski): 1 | Molecular Weight (mw) | 131.17 | ||||||||||||||||||||||
Topological Polar Surface Area (xlogp) | -3 | |||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 5 | |||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 2 | |||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 3 | |||||||||||||||||||||||
ADMET Property |
|
|||||||||||||||||||||||
Chemical Identifiers |
|
|||||||||||||||||||||||
Cross-matching ID | ||||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
|||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | ||||||||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Bleeding disorder | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | GA20-GA21 | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||
Drug-Drug Interaction (DDI) Information of This Drug
Coadministration of a Drug Treating the Disease Different from Aminocaproic acid (Comorbidity)
|
Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug
References
1 | The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954. | ||||
---|---|---|---|---|---|
2 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6574). | ||||
3 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 071192. | ||||
4 | BDDCS applied to over 900 drugs | ||||
5 | An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9. | ||||
6 | Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds | ||||
7 | Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose | ||||
8 | The blockage of the high-affinity lysine binding sites of plasminogen by EACA significantly inhibits prourokinase-induced plasminogen activation. Biochim Biophys Acta. 2002 Apr 29;1596(2):182-92. | ||||
9 | Analysis of plasmin binding and urokinase activation of plasminogen bound to the Heymann nephritis autoantigen, gp330. Arch Biochem Biophys. 1992 Dec;299(2):255-60. | ||||
10 | How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. | ||||
11 | Development of serine protease inhibitors displaying a multicentered short (<2.3 A) hydrogen bond binding mode: inhibitors of urokinase-type plasmi... J Med Chem. 2001 Aug 16;44(17):2753-71. | ||||
12 | Selective urokinase-type plasminogen activator inhibitors. 4. 1-(7-sulfonamidoisoquinolinyl)guanidines. J Med Chem. 2007 May 17;50(10):2341-51. | ||||
13 | Aroylguanidine-based factor Xa inhibitors: the discovery of BMS-344577. Bioorg Med Chem Lett. 2009 Dec 15;19(24):6882-9. | ||||
14 | Selective urokinase-type plasminogen activator (uPA) inhibitors. Part 3: 1-isoquinolinylguanidines. Bioorg Med Chem Lett. 2004 Jun 21;14(12):3227-30. | ||||
15 | The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. | ||||
16 | Selective urokinase-type plasminogen activator (uPA) inhibitors. Part 1: 2-Pyridinylguanidines. Bioorg Med Chem Lett. 2002 Jan 21;12(2):181-4. | ||||
17 | Tranexamic acid in trauma: how should we use it. J Trauma Acute Care Surg. 2013 Jun;74(6):1575-86. | ||||
18 | Acute anuric renal failure with streptokinase therapy in a patient with acute venous thromboembolic disease and the review of renal side effects of streptokinase. Tuberk Toraks. 2008;56(4):456-61. | ||||
19 | Evaluation of aprotinin and tranexamic acid in different in vitro and in vivo models of fibrinolysis, coagulation and thrombus formation. J Thromb Haemost. 2007 Oct;5(10):2113-8. | ||||
20 | Thrombolytic therapies: the current state of affairs. J Endovasc Ther. 2005 Apr;12(2):224-32. | ||||
21 | Evaluation of thrombolytic agents. Drugs. 1997;54 Suppl 3:11-6; discussion 16-7. | ||||
22 | Fibrin binding and the regulation of plasminogen activators during thrombolytic therapy. Cardiovasc Hematol Agents Med Chem. 2008 Jul;6(3):212-23. | ||||
23 | Orally active thrombin inhibitors. Part 1: optimization of the P1-moiety. Bioorg Med Chem Lett. 2006 May 15;16(10):2641-7. | ||||
24 | Vampire bat salivary plasminogen activator (desmoteplase): a unique fibrinolytic enzyme that does not promote neurodegeneration. Stroke. 2003 Feb;34(2):537-43. | ||||
25 | Structure and function of the plasminogen/plasmin system. Thromb Haemost. 2005 Apr;93(4):647-54. | ||||
26 | Cerner Multum, Inc. "Australian Product Information.". | ||||